Leerink Swann Upgrades IDEXX Laboratories (IDXX) to Outperform; Recovering Vet Market

Article Stock Quotes (1) Comments (0)

Leerink Swann upgraded IDEXX Laboratories (NASDAQ: IDXX) from Market Perform to Outperform with a price target raised from $90 to $106.

Analyst, Rick Wise, said, "Driving our positive stance on IDXX: (1) a unique franchise—with very strong market shares, (2) a possibly recovering economy and vet market, (3) a strong track record of innovation, (4) outstanding management team—steered IDXX through growth even in a declining vet market, (5) top-notch return profile —with ROIC at ~22%---among the strongest in our universe, and a track record of consistent share repurchases."

Raises FY12 EPS estimates from $3.10 to $3.12 and FY13 from $3.52 to $3.54.

For an analyst ratings summary and ratings history on IDEXX Laboratories click here. For more ratings news on IDEXX Laboratories click here.

Shares of IDEXX Laboratories closed at $86.44 yesterday, with a 52 week range of $63.83-$89.50.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
• UPDATE: JPMorgan Cuts SodaStream (SODA) to Neutral, 'Stock No Longer Cheap'
• The ExOne Company (XONE) Metal Opportunity to Keep Stock Going - FBR

Create E-mail Alert Related Categories

Analyst EPS Change, Analyst EPS View, Analyst PT Change, Upgrades

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?